Trial Profile
A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Prader-Willi syndrome
- Focus Adverse reactions
- Sponsors Benuvia Therapeutics; INSYS Therapeutics, Inc; Radius
- 22 Apr 2021 According to a Radius Health Inc media release, preliminary results will be presented at PWSA/USA Virtual Medical and Scientific Meeting.
- 11 Nov 2020 Status changed from recruiting to discontinued.
- 30 Aug 2018 Status changed from not yet recruiting to recruiting.